Souvenaid as an add-on intervention in patients with mild to moderate Alzheimer’s disease using Alzheimer’s disease medication: results from a randomized, controlled, double-blind study

The results of S-Connect were published in Alzheimer’s research and therapy in 2013



To evaluate the efficacy and safety of Souvenaid on cognitive function in patients with mild-to-moderate Alzheimer’s disease over a 24-week period.


Study design

Patients with mild-moderate AD, stable on AD medication



The S-Connect study was a 24-week randomised, controlled, double-blind trial in 527 patients with mild-to-moderate Alzheimer’s disease: MMSE scores ranging from 14-24. All patients were stable on AChEI and/or NMDA-antagonist for 4 months prior to baseline and expected stable use throughout the entire study period.

Primary Outcome on cognition

  • 11-item Alzheimer’s disease Assessment Scale – cognitive subscale (ADAS-Cog)

Secondary Outcomes

  • Nutritional measures (blood nutritional markets indicating uptake)
  • Functional abilities
  • Global clinical impression


Souvenaid was well tolerated in combination with standard medication for Alzheimer’s disease. Patient compliance was >90% in both groups. No difference was observed between the Souvenaid and control group on the primary outcome measure.


Souvenaid intake over 24 weeks did not slow cognitive decline in patients treated for mild to moderate Alzheimer’s disease but it was well tolerated in combination with standard care Alzheimer’s medication.


Related Links:


1.Shah, R. C., Kamphuis, P. J., Leurgans, S., Swinkels, S. H., Sadowsky, C. H., Bongers, A., … & Bennett, D. A. The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer’s disease. Alzheimer’s research & therapy, 2013; 5(6), 59.